Illumina illegally monopolised DNA sequencing market, rival says

Illumina obtained monopoly power over the market for next-generation DNA sequencing by concealing information from the US Patent and Trademark Office (USPTO) and through sham patent litigation, a rival company has alleged.


Get unlimited access to all Global Competition Review content